Medivation Inc. hit a little snag on the way to its pivotal phase II study testing supposed PD-1 inhibitor MDV9300 (pidilizumab) in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) when the company concluded the drug does not actually inhibit PD-1 after all.